对肝硬化上消化道出血患者采取特利加压素联合埃索美拉唑的疗效分析  

Therapeutic Effect Analysis of Terlipressin Combined with Esomeprazole in Patients with UpperGastrointestinal Bleeding from Cirrhosis

作　　者：张娟 ZHANG Juan(The 9th Department of Liver Disease,Dalian Sixth People's Hospital,Dalian 116000,China)

机构地区：[1]大连市第六人民医院肝病九科,辽宁大连116000

出　　处：《中国医药指南》2021年第9期29-30,共2页Guide of China Medicine

摘　　要：目的探讨肝硬化上消化道出血患者采取特利加压素联合埃索美拉唑的疗效分析。方法选取在辽宁省大连市第六人民医院肝病九科住院的80例患者为研究对象,时间为2018年1月至2019年1月,随机分为试验组和对照组。对照组40例,采取埃索美拉唑治疗,试验组40例肝硬化上消化道出血患者在使用埃索美拉唑治疗的基础上加用特利加压素治疗。记录两组患者的临床疗效和外周血细胞和肌酐水平以及不良反应发生率。结果试验组的临床疗效高于对照组(P<0.05)。试验组患者的RBC、Hb以及血肌酐水平高于对照组患者(P<0.05)。结论对肝硬化上消化道出血患者采取特利加压素联合埃索美拉唑,临床运用效果显著,值得在临床推广。Objective To investigate the efficacy of terlipressin combined with esomeprazole in patients with upper gastrointestinal hemorrhage due to liver cirrhosis.Methods From January 2018 to January 2019 in Dalian Sixth People's Hospital,were randomly divided into experimental group and control group.Forty cases in the control group were treated with esomeprazole,and 40 cases in the experimental group were treated with terlipressin on the basis of esomeprazole.Record the clinical curative effect of two groups of patients and peripheral blood cells and creatinine levels and the incidence of adverse reactions.Results The clinical efficacy of the experimental group was higher than that of the control group(P<0.05).The RBC,Hb and serum creatinine levels in the experimental group were higher than those in the control group(P<0.05).Conclusion Terlipressin combined with esomeprazole in patients with upper gastrointestinal bleeding due to cirrhosis has significant clinical effects and is worthy of clinical promotion.

关 键 词：肝硬化 上消化道出血 特利加压素 埃索美拉唑 

分 类 号：R657.31[医药卫生—外科学]